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QUANTIFYING COST OUTCOMES DIFFERENTIATED BY GENDER AND AGE IN
THE TREATMENT OF MIGRAINE HEADACHE USING STEP AND STRATIFIED
CARE
Furiak N, Bansal M
Medical Decision Modeling Inc., Indianapolis, IN, USA
OBJECTIVES:The objective of this studywas to estimate the cost savings of STEP vs.
Stratified (STRAT) migraine headache care differentiated by age and gender.
METHODS: Migraine headaches are a prevalent disorder resulting direct costs of
$2,571 per person per year on average which includes hospital visits and prescrip-
tion drug costs. The indirect costs ofmigraine headaches are estimated to be about
$13 billion a year indirectly affecting theworkplace through an estimated $8 billion
due to missed word days alone. A Monte Carlo microsimulation based upon previ-
ously published non-U.S. models was developed to evaluate the cost-benefit of
stratified care based on MIDAS scores vs. the more commonly applied step care.
Although STEP care delays the initiation of triptan therapywhich is generallymore
costly and potentially habit forming, there may be cost-benefit from evaluating
patient history and disease severity throughMIDAS scores and advancing patients
to more advanced therapies in severe cases. RESULTS: As expected, the greatest
cost differences when adopting STRAT was for MIDAS III women age 40-49 due to
the peak prevalence at this age/gender (STRAT vs. STEP $547 vs. $1,572 per case)
with similar trend found for males of the same age ($515 vs. $1,464). However, the
cost differences for STRAT vs. STEP care for aged 60was significant ($136 vs. $326)
and the difference for patients (age 12-17) was $199. Adoption of STRAT care in
routine clinical practice yields differences of $1,025 and $949 per patient per year
for females and males respectively. Further evidence shows that cost differences
for those ages 60 were $190, and those under age 30 were $199. CONCLUSIONS:
Although the differences for the latter two age strata were smaller, they may have
implications for specialized populations such as Medicare and Medicaid and the
impact they have on plan budgets.
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ECONOMIC EVALUATION OF DEXMEDETOMIDINE FOR SEDATION IN THE
INTENSIVE CARE UNIT
Lachaine J, Beauchemin C
University of Montreal, Montreal, QC, Canada
OBJECTIVES: Dexmedetomidine is an alpha-2 receptor agonist used in continuous
infusion for the sedation of critically ill patients in intensive care unit who are
intubated andmechanically ventilated. Compared tomidazolam in the sedation of
intensive care unit patients, dexmedetomidine showed a decrease in time spent on
ventilator, fewer episodes of delirium and reduced incidence of tachycardia and
hypertension. The aim of this study was to assess the economic impact, in a Ca-
nadian context, of dexmedetomidine for sedation in intensive unit care compare
with midazolam, a GABA agonist. METHODS: This economic evaluation was per-
formed using a cost-consequences analysis, according the perspective of Canadian
Health Care system. The time horizon chosen is an intensive care unit stay with a
maximum length of 30 days. Clinical data were obtained from a prospective ran-
domized, double-blinded trial by Riker and al. comparing dexmedetomidine and
midazolam. Costs considered in this evaluation were those of the medications, of
the mechanical ventilation, of the delirium episodes, and those associated with
adverse events requiring an intervention. All costs were adjusted to 2010 and were
reported in Canadian dollars. RESULTS: The average cost ofmedicationwas higher
with dexmedetomidine ($1,930) than with midazolam ($180), but the average cost
associated with mechanical ventilation and with the management of delirium
were lower with dexmedetomidine ($2,939 and $3,630 respectively) than with
midazolam ($4,448 and $5,149). Overall cost per patient with dexmedetomidine
($8,525) was lower thanwithmidazolam ($9,817). Deterministic sensitivity analysis
confirmed the robustness of this difference. CONCLUSIONS: The results of this
cost-consequences analysis indicated that the use of dexmedetomidine is a favor-
able strategy in terms of clinical consequences and economic impact compare to
midazolam. Compared to midazolam, dexmedetomidine is a less expensive strat-
egy associated with a lower occurrence of delirium and a shorter duration of me-
chanical ventilation.
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QUALITY OF LIFE USING TREATMENTS FOR PARKINSON’S DISEASE: AN
ECONOMIC COMPARISON BETWEEN ROPINIROLE AND LEVODOPA/CARBIDOPA
Patil DS, Shah AJ, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: Parkinson’s disease(PD) is the second common neuro-degenerative
disease in US older adults. Until recently, Levodopa was the only treatment for PD.
Although, Ropinirole is approved by FDA for PD, there are no cost-effectiveness
studies comparing these treatments. The objective of our study is to perform cost-
effectiveness analysis comparing Ropinirole and the combination therapy of
Levodopa/Carbidopa in the treatment of PD.METHODS: A cost-effectiveness anal-
ysis was performed from the patient’s perspective to compare Ropinirole and
Levodopa/Carbidopa treatment in PD patients using a decision tree model as a
pragmatic tool to derive comparative information on the costs and effectiveness of
these two strategies over a 5-year period. A predictive model was developed to
capture utilization, such asmedication(drug) costs, physician costs, caregiver time,
and productivity loss. Clinical information was derived from a comparative effec-
tiveness study. All direct and indirect costs were obtained from pharmacists, pub-
lished literature, and medical practitioners. Effectiveness was measured in terms
of quality adjusted life years(QALY) reported in literature. Costs were adjusted to
2009 U.S. dollars. One way and two way sensitivity analyses with 25% change in
cost and 20% change in QALY values were performed and incremental cost effec-
tiveness ratio(ICER) was calculated. RESULTS: The Ropinirole therapy resulted in a
gain of 2.82 QALY’s at a cost of $107,062 compared to Levodpo/Carbidopa combi-
nation therapy which resulted in a gain of 2.35 QALY’s at a cost of $102,423 at the
end of 5 years. The expected cost per QALYwas $37,965 for Ropinirole while that of
Levodopa/Carbidopa combination was $43,584. One way and two way analyses
were consistent, validating the results. ICER was found to be $9,870 per QALY for
switching from Ropinirole to Levodopa/Carbidopa therapy. CONCLUSIONS: Our
cost-effectiveness analysis indicates that Ropinirole is a better option as compared
to Levodopa/Carbidopa for treatment of patient suffering from PD.
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ECONOMIC TRENDS ASSOCIATED WITH NATALIZUMAB THERAPY IN A
COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION
Pill M, Gilkin B
Gemini Healthcare, LLC, Westbrook, CT, USA
OBJECTIVES: Identify a population of multiple sclerosis (MS) patients new to treat-
ment with natalizumab. Observe and record healthcare costs before initiation of
natalizumab and up to 3 years after continuing treatment. Compare and quantify
differences in costs based on patterns of natalizumab use.METHODS: Using inte-
grated medical and pharmacy claims data (IMS LifeLink™ Health Plan Claims and
Longitudinal Prescriptions databases), patients were included in the analysis based on
the presence of a diagnosis of MS (ICD-9 code 340.*) during calendar years 2005
through 2008. Economic information related to the treatment of MS was captured
using the Episode Treatment Group™ software. RESULTS: From the database, 76
MS patients that started natalizumab treatment and had 4 full calendar years of
data were observed. These patients were observed for the year prior to start of
natalizumab treatment in 2006, through the end of the 2008 calendar year. Patients
were stratified by continued use of natalizumab during the study period. For all
patients, there were significant increases in annual pharmacy costs ($17,667 to
$40,399) during the year natalizumab treatment was initiated, in addition to out-
patient medical services ($8,383 to $11,744). For patients who continued natali-
zumab for the entire study period, inpatient costs decreased from $2,630 to an
average of $5 per year; emergency room costs in this group also decreased from a
maximum of $537 to $218 annually. For patients who discontinued natalizumab
during the study period, there were increased inpatient costs after discontinuation
($2,630 to $6,701). CONCLUSIONS: Though the study size is small, the cost obser-
vations can enable decision-makers to better understand costs associatedwith the
short and longer-term use of natalizumab for the treatment of MS.
PND26
MEASURING THE IMPACT OF NATALIZUMAB THERAPY ON HEALTH CARE
UTILIZATION IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS
POPULATION
Pill M, Gilkin B
Gemini Healthcare, LLC, Westbrook, CT, USA
OBJECTIVES: Identify a population of MS patients new to treatment with natali-
zumab. Observe and record healthcare utilization before initiation of natalizumab
and up to 1 year after continuing treatment. Compare and quantify differences in
healthcare utilization for the period prior to natalizumab treatment through the
following calendar year. METHODS: Using integrated medical and pharmacy
claims data (IMS LifeLink™Health Plan Claims and Longitudinal Prescriptions databases),
patients were included in the analysis based on the presence of a diagnosis of MS
(ICD-9 code 340.*) during calendar years 2006 through 2008. Clinical and utilization
information related to the treatment of MS were captured using the Episode Treat-
ment Group™ (ETG™) episode-building software.RESULTS: From the database, 349
MS patients that were both new to natalizumab treatment in 2007 and had 3 full
calendar years of data were observed. In the year of treatment initiation with
natalizumab, therewas an overall increase in the number of prescriptions received
(14.0 to 22.6 per year), aswell outpatientmedical services (16.1 to 25.6) whichwould
be expected with starting a newMS therapy. In addition to these increases, ER and
inpatient utilization were also on the rise prior to initiation of natalizumab, how-
ever, utilization of ER and inpatient services significantly decreased in the follow-
ing calendar year. During this period, there were also significant decreases in the
amount of drugs used for supportive care ofMS including corticosteroids, antispas-
tic agents, and benzodiazepines. CONCLUSIONS: Healthcare costs were at their
highest in the year natalizumab was initiated. Following initiation of natalizumab
therapy, there was a decrease in ER, inpatient and supportive care utilization.
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MEDICO-ECONOMIC EVALUATION OF LACOSAMIDE ADJUNCTIVE THERAPY IN
THE TREATMENT OF PATIENTS WITH REFRACTORY EPILEPSY IN THE UNITED
STATES
Benhaddi H1, Helmers S2
1UCB Group, Brussels, Belgium, 2Emory University School of Medicine, Atlanta, GA, USA
OBJECTIVES: To calculate and compare the incremental cost-utility ratios for stan-
dard antiepileptic drug (AED) therapy with and without adjunctive lacosamide in
patients with uncontrolled partial-onset seizures. METHODS: The model simu-
lated the treatment pathway of a hypothetical cohort of 1000 patients over two
years from the third party payer perspective in theUnited States in 2010. A decision
tree was split into four phases of six months each during which patients can be-
come seizure free, experience a seizure reduction (responder defined as >50%
reduction in seizures), or withdraw due to non-response. The standard therapy
arm included five adjunctive therapies: carbamazepine, lamotrigine, levetirac-
etam, topiramate, and valproate. The likelihood of being in a particular health state
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